• Jazz Pharmaceuticals will present neuro-oncology research at the Society for Neuro-Oncology meeting November 12-15, 2026, in Philadelphia.
• The Phase 3 ACTION trial of Modeyso in newly diagnosed H3 K27M-mutant diffuse glioma is advancing toward interim analysis in early 2027.
• A Phase 2 trial of JZP3507 has begun in adults with recurrent grade 2 or 3 meningioma.
• Upcoming preclinical findings show JZP3507 demonstrated anticancer activity in H3 G34-mutant glioma cells.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Jazz Pharmaceuticals plc published the original content used to generate this news brief via PR Newswire (Ref. ID: 202611020830PR_NEWS_USPR_____SF85745) on November 02, 2026, and is solely responsible for the information contained therein.